Experimental ovarian cancer drug combo studied in early trial

NCT ID NCT05200364

Terminated Disease control Sponsor: Sutro Biopharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested a new drug called STRO-002 combined with Avastin (bevacizumab) in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the right dose. The study was terminated early, so while it gathered some safety data, it does not yet show whether the combination works better than existing treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STRO-002 (an antibody-drug conjugate) combined with bevacizumab (Avastin)
What this could lead to: If successful, this combination could offer a new treatment option for advanced ovarian cancer that has stopped responding to other therapies.
What could go wrong: This was a very early (Phase 1) trial focused on safety and dosing, not effectiveness. The study was terminated early, so results are limited and may not lead to a standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm ovarian cancer ovarian carcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER OVARIAN CANCER OVARIAN CARCINOMA OVARY CANCER PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Tennessee Oncology

Nashville, Tennessee, 37203, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19017, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of South Florida,

Tampa, Florida, 33612, United States
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.